1. Home
  2. IMNN

as of 12-12-2025 11:45am EST

$4.20
+$0.07
+1.69%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Chart Type:
Time Range:
Founded: 1982 Country:
United States
United States
Employees: N/A City: LAWRENCEVILLE
Market Cap: 12.9M IPO Year: 1985
Target Price: $182.61 AVG Volume (30 days): 33.4K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -9.54 EPS Growth: N/A
52 Week Low/High: $3.56 - $41.22 Next Earning Date: 11-13-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered IMNN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 67.88%
67.88%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: